BeOne Medicines received FDA accelerated approval for BEQALZI (sonrotoclax) to treat adults with relapsed or refractory mantle cell lymphoma after prior BTK inhibitor therapy, supported by Phase 1/2 data showing a 52% overall response rate.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
BeOne Medicines has received accelerated approval from the U.S. Food and Drug Administration (FDA) for BEQALZI (sonrotoclax) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Sonrotoclax is a next-generation BCL2 inhibitor developed to provide more potent and selective BCL2 inhibition, with a pharmacologic profile aimed at improving efficacy, tolerability, and treatment convenience compared with earlier therapies in the class. The approval addresses an unmet need in patients with MCL whose disease progresses after BTK inhibitor treatment, a setting associated with limited treatment options and poor outcomes.
The FDA decision was supported by data from the Phase 1/2 BGB-11417-201 study (NCT05471843), which evaluated sonrotoclax monotherapy in patients with relapsed or refractory MCL. Results presented at the 67th American Society of Hematology Annual Meeting showed an overall response rate of 52% and a complete response rate of 16%. Patients achieved a median time to response of 1.9 months, while the median duration of response was 15.8 months at a median follow-up of 11.9 months. Investigators also reported that the treatment was generally well tolerated.
Michael Wang, M.D., Global Principal Investigator, said the approval provides an additional treatment option for patients in the post-BTK inhibitor setting who have limited remaining therapies.
Continued approval for this indication will depend on confirmation of clinical benefit in the ongoing Phase 3 CELESTIAL-RRMCL trial (NCT06742996). The FDA had previously granted sonrotoclax Breakthrough Therapy, Fast Track, and Orphan Drug designations for MCL.
Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said the approval of BEQALZI marks an important step in advancing BCL2-targeted therapies for patients with B-cell malignancies, including mantle cell lymphoma.
Meghan Gutierrez, Chief Executive Officer, Lymphoma Research Foundation, said the approval provides a new treatment option for patients with relapsed or refractory mantle cell lymphoma who have limited remaining therapies and highlights the need for continued research in the disease.
Mantle cell lymphoma is a rare and aggressive subtype of non-Hodgkin lymphoma, with around 3,300 new cases diagnosed annually in the United States. Relapse remains common despite initial responses to treatment.
Sonrotoclax is also approved in China for relapsed or refractory MCL and previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. The therapy is under regulatory review in Europe and other regions. In addition, BeOne Medicines is studying sonrotoclax in combination regimens, including with zanubrutinib for chronic lymphocytic leukemia.
References
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.